| Q38998772 | A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria |
| Q35945244 | Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant |
| Q44185167 | Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial |
| Q37012863 | Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay. |
| Q43230300 | Dihydrofolate reductase I164L mutation in Plasmodium falciparum, Madagascar |
| Q46717613 | Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation |
| Q35129708 | Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania |
| Q28125930 | High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania |
| Q35545447 | History, dynamics, and public health importance of malaria parasite resistance |
| Q34114498 | Identification of pyrimethamine- and chloroquine-resistant Plasmodium falciparum in Africa between 1984 and 1998: genotyping of archive blood samples |
| Q37333178 | In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation |
| Q35338819 | In vitro susceptibility to pyrimethamine of DHFR I164L single mutant Plasmodium falciparum |
| Q24806194 | Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa |
| Q24807035 | Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop |
| Q33935361 | Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi |
| Q37685088 | Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough? |
| Q41943140 | Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro |
| Q36717628 | Reducing the burden of malaria in pregnancy by preventive strategies |
| Q36936842 | Secondary mutations correct fitness defects in Toxoplasma gondii with dinitroaniline resistance mutations |
| Q28474692 | Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya |
| Q37315266 | Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania |
| Q36075911 | Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? |